RESUMEN
Clinical guidelines do not clearly define hospitalization time after primary angioplasty in ST-segment elevation myocardial infarction (STEMI). The hospitalization time should be tailored according to risk stratification. AIM: Evaluation of a local early discharge protocol to identify low-risk patients after primary angioplasty. METHODS: A local protocol was applied to all patients admitted to Las Higueras Hospital after primary angioplasty in the context of STEMI from the Health Service of Talcahuano (Those belonging to other Health Services were excluded). Those who met the established criteria were discharged < 48 hours. Clinical variables, comorbidities, angiographic characteristics, and the procedure, as well as intraoperative complications, mortality, and hospital readmission up to 6 months, were analyzed. RESULTS: A total of 51 patients were identified, with a mean age of 59.5 years and 25% female. The mean ischemia time was 5.5 hours with a risk profile that showed a mean GRACE score of 106 and a Zwolle risk score of 1.7. The mean length of stay was 1.7 days (40.8 h). There was only 1 readmission and no mortality events were registered up to 6 months of follow-up. CONCLUSION: The application of a protocol for early discharge after primary angioplasty allowed for shorter hospital stays without compromising patient safety in the medium term.
Asunto(s)
Tiempo de Internación , Alta del Paciente , Infarto del Miocardio con Elevación del ST , Humanos , Femenino , Masculino , Infarto del Miocardio con Elevación del ST/terapia , Infarto del Miocardio con Elevación del ST/mortalidad , Persona de Mediana Edad , Factores de Tiempo , Tiempo de Internación/estadística & datos numéricos , Anciano , Protocolos Clínicos/normas , Factores de Riesgo , Medición de Riesgo , Readmisión del Paciente/estadística & datos numéricos , Resultado del TratamientoRESUMEN
The indication for percutaneous aortic valve implantation (TAVI) has increased considerably in recent years, preferably using transfemoral access (TF); however, it is not clear which should be the preferred access in the event of contraindications to the latter. We present an 81-year-old patient with high surgical risk in whom a 50% obstruction of the descending aortic lumen was identified and so, a left transcarotid access was chosen. Numerous alternative approaches to the TF approach have been described in recent years. The transcarotid approach has been the one with the best results in different clinical reviews and the one that has been presented as the second alternative to TF in established algorithms. We report the first transcarotid TAVI implantation in Las Higueras Hospital, Talcahuano, Chile.
Asunto(s)
Estenosis de la Válvula Aórtica , Reemplazo de la Válvula Aórtica Transcatéter , Humanos , Anciano de 80 o más Años , Reemplazo de la Válvula Aórtica Transcatéter/métodos , Estenosis de la Válvula Aórtica/cirugía , Chile , Resultado del Tratamiento , Masculino , Arterias Carótidas/cirugíaRESUMEN
BACKGROUND: In those patients who do not have timely access to primary angioplasty, the pharmaco-invasive approach, that is, the use of thrombolysis as a bridging measure prior to the coronary angiography, is a safe alternative. AIM: To describe the features of patients with an acute ST-elevation myocardial infarction (STEMI) treated with a pharmaco-invasive strategy. MATERIAL AND METHODS: Descriptive observational study of 144 patients with mean age of 46 years with STEMI who received a dose of thrombolytic prior to their referral for primary angioplasty at a public hospital between 2018 and 2021. RESULTS: There were no differences the clinical presentation according to the Killip score at admission between thrombolyzed and non-thrombolyzed patients (p = ns). Fifty-three percent of non-thrombolyzed patients were admitted with an occluded vessel (TIMI 0) compared with 27% of thrombolyzed patients (p < 0.001). The thrombolyzed group required significantly less use of thromboaspiration (3.5 and 8.4% respectively; p = 0.014). Despite this, 91 and 92% of non-thrombolyzed and thrombolyzed patients achieved a post-angioplasty TIMI 3 flow. Long-term survival was 91 and 86% in thrombolyzed and non-thrombolyzed patients, respectively (p = ns). CONCLUSIONS: The pharmaco-invasive strategy is a safe alternative when compared to primary angioplasty in centers that don't have timely access to Interventional Cardiology.
Asunto(s)
Infarto del Miocardio , Infarto del Miocardio con Elevación del ST , Humanos , Persona de Mediana Edad , Infarto del Miocardio con Elevación del ST/tratamiento farmacológico , Terapia Trombolítica , Infarto del Miocardio/tratamiento farmacológico , Fibrinolíticos/uso terapéutico , Resultado del Tratamiento , Angiografía CoronariaRESUMEN
BACKGROUND: Transfemoral transcatheter aortic valve implantation (TAVI) is the standard of treatment for patients with symptomatic severe aortic stenosis (AE) and intermediate or high surgical risk. The use of conscious sedation (CS) could reduce complications and allow an early discharge of these patients. AIM: To report our experience with TAVI under conscious sedation. MATERIAL AND METHODS: Review of medical records of 15 patients aged 79 ± 6 years (53% women) undergoing a transfemoral TAVI implant under conscious sedation. RESULTS: The indications for the procedure were severe AE in 13 patients and biological prosthetic dysfunction in two. The mean Thoracic Surgeons predicted risk of mortality score was 7.3. The valves used were Edwards Sapien 3 in three patients, Medtronic Evolut in five, Boston Acurate Neo in four and Meril Myval in three. A successful implant was achieved in all cases and there were no hospital mortality or pacemaker requirements. One patient had a stroke, and one patient had a vascular access complication. Early discharge (< 72 h) was achieved in 80% of patients. CONCLUSIONS: TAVI under conscious sedation was a safe procedure and associated with a complication rate similar to previous reports, allowing for an early hospital discharge in most patients.
Asunto(s)
Estenosis de la Válvula Aórtica , Prótesis Valvulares Cardíacas , Reemplazo de la Válvula Aórtica Transcatéter , Estenosis de la Válvula Aórtica/cirugía , Sedación Consciente , Femenino , Humanos , Masculino , Resultado del TratamientoRESUMEN
The deployment of a percutaneous aortic valve is challenging in patients with a mitral prosthesis. The risk of prosthetic deformation, embolization or dysfunction is higher in this group of patients, which requires a series of technical considerations. We report a successful implantation of an Evolut Pro # 29 self-expanding valve in a 67-year-old female with a previous Starr-Edwards caged-ball mitral prosthesis.
Asunto(s)
Implantación de Prótesis de Válvulas Cardíacas , Prótesis Valvulares Cardíacas , Anciano , Válvula Aórtica/diagnóstico por imagen , Válvula Aórtica/cirugía , Femenino , Humanos , Válvula Mitral/diagnóstico por imagen , Válvula Mitral/cirugía , Diseño de PrótesisRESUMEN
We report a 55-year-old woman with a history of hypothyroidism and type 2 diabetes mellitus who consulted at the emergency room because of intermittent oppressive chest discomfort. At admission, electrocardiogram showed a complete atrioventricular block. A transthoracic echocardiogram disclosed severe left ventricular dysfunction. The patient developed cardiogenic shock that required the installation of the Impella system. An emergency coronary angiography showed an ostial occlusion of the anterior descending artery. Despite successful primary angioplasty, she persisted with refractory shock and progressive hypoxemia. A concomitant connection to the extracorporeal membrane oxygenation system (ECMO) was decided. The support of both devices allowed the stabilization of the patient and the improvement of perfusion parameters.
Asunto(s)
Corazón Auxiliar , Choque Cardiogénico/terapia , Disfunción Ventricular Izquierda , Diabetes Mellitus Tipo 2 , Oxigenación por Membrana Extracorpórea , Femenino , Humanos , Persona de Mediana EdadRESUMEN
La indicación en el implante de la válvula aortica percutánea (TAVI) se ha incrementado considerablemente en los últimos años, utilizando de preferencia el acceso transfemoral (TF), sin embargo, no queda claro cual debería ser la 2 vía de preferencia ante contraindicaciones a esta última. Presentamos un paciente de 81 años con alto riesgo quirúrgico en quien luego de discusión con heart team se decidió realizar TAVI y posterior a la identificación de obstrucción de la luz aortica descendente de 50%, se decidido realizar acceso transcarotideo izquierdo. Numerosos abordajes alternativos a la vía TF han sido descriptos en los últimos años. La vía transcarotidea ha sido la de mejores resultados en distintas revisiones clínicas y la que se ha presentado como 2° alternativa a la TF en algoritmos establecidos. Reportamos el primer implante de TAVI por vía transcarotidea en el hospital las Higueras, Chile.
The indication for percutaneous aortic valve implantation (TAVI) has increased considerably in recent years, preferably using transfemoral access (TF); however, it is not clear which should be the preferred access in the event of contraindications to the latter. We present an 81-year-old patient with high surgical risk in whom a 50% obstruction of the descending aortic lumen was identified and so, a left transcarotid access was chosen. Numerous alternative approaches to the TF approach have been described in recent years. The transcarotid approach has been the one with the best results in different clinical reviews and the one that has been presented as the second alternative to TF in established algorithms. We report the first transcarotid TAVI implantation in Las Higueras Hospital, Talcahuano, Chile.
Asunto(s)
Humanos , Masculino , Anciano de 80 o más Años , Estenosis de la Válvula Aórtica/cirugía , Reemplazo de la Válvula Aórtica Transcatéter/métodos , Arterias Carótidas/cirugía , Chile , Resultado del TratamientoRESUMEN
BACKGROUND: In those patients who do not have timely access to primary angioplasty, the pharmaco-invasive approach, that is, the use of thrombolysis as a bridging measure prior to the coronary angiography, is a safe alternative. AIM: To describe the features of patients with an acute ST-elevation myocardial infarction (STEMI) treated with a pharmaco-invasive strategy. MATERIAL AND METHODS: Descriptive observational study of 144 patients with mean age of 46 years with STEMI who received a dose of thrombolytic prior to their referral for primary angioplasty at a public hospital between 2018 and 2021. RESULTS: There were no differences the clinical presentation according to the Killip score at admission between thrombolyzed and non-thrombolyzed patients (p = ns). Fifty-three percent of non-thrombolyzed patients were admitted with an occluded vessel (TIMI 0) compared with 27% of thrombolyzed patients (p < 0.001). The thrombolyzed group required significantly less use of thromboaspiration (3.5 and 8.4% respectively; p = 0.014). Despite this, 91 and 92% of non-thrombolyzed and thrombolyzed patients achieved a post-angioplasty TIMI 3 flow. Long-term survival was 91 and 86% in thrombolyzed and non-thrombolyzed patients, respectively (p = ns). CONCLUSIONS: The pharmaco-invasive strategy is a safe alternative when compared to primary angioplasty in centers that don't have timely access to Interventional Cardiology.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Infarto del Miocardio con Elevación del ST/tratamiento farmacológico , Análisis de Supervivencia , Terapia Trombolítica , Resultado del Tratamiento , Angiografía Coronaria , Fibrinolíticos/uso terapéutico , Infarto del Miocardio/tratamiento farmacológicoRESUMEN
Background: Transfemoral transcatheter aortic valve implantation (TAVI) is the standard of treatment for patients with symptomatic severe aortic stenosis (AE) and intermediate or high surgical risk. The use of conscious sedation (CS) could reduce complications and allow an early discharge of these patients. Aim: To report our experience with TAVI under conscious sedation. Material and Methods: Review of medical records of 15 patients aged 79 ± 6 years (53% women) undergoing a transfemoral TAVI implant under conscious sedation. Results: The indications for the procedure were severe AE in 13 patients and biological prosthetic dysfunction in two. The mean Thoracic Surgeons predicted risk of mortality score was 7.3. The valves used were Edwards Sapien 3 in three patients, Medtronic Evolut in five, Boston Acurate Neo in four and Meril Myval in three. A successful implant was achieved in all cases and there were no hospital mortality or pacemaker requirements. One patient had a stroke, and one patient had a vascular access complication. Early discharge (< 72 h) was achieved in 80% of patients. Conclusions: TAVI under conscious sedation was a safe procedure and associated with a complication rate similar to previous reports, allowing for an early hospital discharge in most patients.
Asunto(s)
Humanos , Masculino , Femenino , Estenosis de la Válvula Aórtica/cirugía , Prótesis Valvulares Cardíacas , Reemplazo de la Válvula Aórtica Transcatéter , Sedación Consciente , Resultado del TratamientoRESUMEN
The deployment of a percutaneous aortic valve is challenging in patients with a mitral prosthesis. The risk of prosthetic deformation, embolization or dysfunction is higher in this group of patients, which requires a series of technical considerations. We report a successful implantation of an Evolut Pro # 29 self-expanding valve in a 67-year-old female with a previous Starr-Edwards caged-ball mitral prosthesis.
Asunto(s)
Humanos , Femenino , Anciano , Prótesis Valvulares Cardíacas , Implantación de Prótesis de Válvulas Cardíacas , Válvula Aórtica/cirugía , Válvula Aórtica/diagnóstico por imagen , Diseño de Prótesis , Válvula Mitral/cirugía , Válvula Mitral/diagnóstico por imagenRESUMEN
We report a 55-year-old woman with a history of hypothyroidism and type 2 diabetes mellitus who consulted at the emergency room because of intermittent oppressive chest discomfort. At admission, electrocardiogram showed a complete atrioventricular block. A transthoracic echocardiogram disclosed severe left ventricular dysfunction. The patient developed cardiogenic shock that required the installation of the Impella system. An emergency coronary angiography showed an ostial occlusion of the anterior descending artery. Despite successful primary angioplasty, she persisted with refractory shock and progressive hypoxemia. A concomitant connection to the extracorporeal membrane oxygenation system (ECMO) was decided. The support of both devices allowed the stabilization of the patient and the improvement of perfusion parameters.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Choque Cardiogénico/terapia , Corazón Auxiliar , Disfunción Ventricular Izquierda , Oxigenación por Membrana Extracorpórea , Diabetes Mellitus Tipo 2Asunto(s)
Aterosclerosis/diagnóstico por imagen , Puente de Arteria Coronaria , Oclusión de Injerto Vascular/diagnóstico por imagen , Vena Safena/trasplante , Anciano , Puente de Arteria Coronaria/efectos adversos , Rechazo de Injerto/etiología , Humanos , Masculino , Vena Safena/diagnóstico por imagen , Tomografía de Coherencia Óptica , Insuficiencia del TratamientoRESUMEN
The aim of this study was to determine whether there is a relationship between prolonged use of metformine on bone mineral density, comparing a group of patients receiving prolonged treatment with metformine and a control group with similar characteristics biodemographic. Material and Methods: A case-control study was conducted in a population of 225 postmenopausal women between 51 and 62 years of age, were divided into 2 groups, one of type 2 diabetic patients treated with 1,000-2,000 mg. of metformine for at least 5 years (n = 75) and they had an acceptable metabolic control (HbA1c < 7.5 percent), and a control group of non diabetic women (n = 150). BMD at the lumbar spine (L1-L4) and both hips were measured with DEXA. Results: The group of type 2 diabetes treated with metfornine was associated with a significantly increased bone mineral density at the lumbar spine compared with the control group (L1-L4 g/cm2 1.07 +/- 0.15 vs 0.16 +/- 0.975) (L1-L4 T score-0.68 +/- 1.06 vs -1.73 +/- 1,07) (p = 0.05).Conclusion: Prolonged therapy metformine could have an effect on the preservation of bone mineral density at the lumbar spine in women with diabetes type 2, suggesting an effect of metfornine osteoprotective in trabecular bone.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Densidad Ósea , /tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Metformina/administración & dosificación , Posmenopausia , Estudios de Casos y Controles , Densitometría , Factores de TiempoRESUMEN
Osteopoikilosis is an infrequent sclerotic bone dysplasia with discrete spherical areas of increased bone density. It has an autosomal, dominant inheritance with variable penetrance. It a diagnosed by the observation of characteristic images on x-ray films. Despite its lack of pathological importance, it must be distinguished from osteoblastic bone metastases, tuberose sclerosis, mastocytosis or sarcoidosis. We report a 23 years old male who presented a right ankle sprain. X-ray films showed important lesions in the trabecular bone of the tarsus, metatarsus and phalanges, as numerous small foci of osteosclerosis. The study was complemented with a pelvis, femur and a hand radiological study with similar findings. These findings led to the diagnosis of osteopoikilosis. Among his family members, x-ray films showed that the mother also carried the disease.